2026-01-22 - Analysis Report
# Merck (MRK) Financial Report

## 1. Return Rate Comparison
- **Cumulative Return (MRK)**: 28.30%
- **Cumulative Return (S&P 500, VOO)**: 91.55%
- **Divergence**: -67.60%
- **Relative Divergence**: 24.20%

**Analysis**: Merck's cumulative return significantly lags behind the S&P 500, indicating underperformance relative to the broader market.

### Alpha, Beta Analysis
| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|-------|
| 2016-2018  | 24.0% | 14.7% | 20.0% | 0.7  | 182.1 |
| 2017-2019  | 37.0% | 14.7% | 19.0% | 0.7  | 216.8 |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7  | 195.0 |
| 2019-2021  | 0.0%  | 19.3% | -43.0%| 0.6  | 191.4 |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5  | 277.1 |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3  | 272.3 |
| 2022-2024  | -5.0% | 24.9% | -24.0%| 0.3  | 248.5 |
| 2023-2025  | -24.0%| 39.0% | -86.0%| 0.3  | 262.9 |

**Analysis**: The CAGR shows variability, with a peak in 2017-2019, but recent years indicate negative growth and increasing maximum drawdown (MDD). 

## 2. Recent Stock Price Fluctuations
- **Close Price**: $111.11 
- **Previous Close**: $109.45 
- **Change**: $1.52
- **5-day SMA**: $110.27
- **20-day SMA**: $108.13
- **60-day SMA**: $99.21

**Analysis**: The stock has shown a positive change recently, with moving averages indicating a gradual upward trend.

## 3. Market Indicators
- **Market Risk Indicator (MRI)**: 0.80 (Medium Investment)
- **RSI**: 64.84
- **PPO**: -0.22
- **Hybrid Signal**: Buy (Cash 0%)
- **Recent Relative Divergence Change**: -1.00 (worsening)
- **7-day Rank Change**: +35 (rank up)
- **7-day Dynamic Expected Return Change**: -2.90 (worsening)
- **Expected Return**: -29.60%

**Analysis**: The RSI suggests a strong position, but the PPO is negative, indicating potential weakness. The expected return is significantly negative, indicating a risk if held long-term.

## 4. Recent News & Significant Events
- Merck stock position boosted by Joel Isaacson & Co. LLC.
- Query on whether Merck stock is a trap at $110.
- Merck added to BofA US 1 List.
- Partnership with CEPI for Ebola vaccine with a $30 million investment.
- Weighing Revolution Medicines buyout and expanding AI oncology bets.
- Discussion on Merck's pricing reflecting long-term value post share price strength.

**Analysis**: Recent news reflects strategic partnerships and market positioning which could influence future performance positively.

## 4-2. Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 114.59 / 135.00 / 83.00
```

## 5. Recent Earnings Analysis
| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

**Analysis**: EPS shows an upward trend with increasing revenues, indicating potential growth in profitability.

## 6. Financial Information
### Revenue and Profitability
| Quarter       | Revenue | Profit Margin |
|---------------|---------|---------------|
| 2025-09-30    | $17.28B | 77.69%        |
| 2025-06-30    | $15.81B | 77.50%        |
| 2025-03-31    | $15.53B | 77.98%        |
| 2024-12-31    | $15.62B | 75.50%        |
| 2024-09-30    | $16.66B | 75.51%        |

### Capital and Profitability
| Quarter       | Equity  | ROE   |
|---------------|---------|-------|
| 2025-09-30    | $51.85B | 11.16%|
| 2025-06-30    | $48.99B | 9.04% |
| 2025-03-31    | $48.34B | 10.51%|
| 2024-12-31    | $46.31B | 8.08% |
| 2024-09-30    | $44.50B | 7.09% |

**Analysis**: Revenue growth is steady with high profit margins, while ROE shows improvement, reflecting better capital efficiency.

## 7. Comprehensive Analysis
Overall, Merck is underperforming compared to the S&P 500 with a considerable divergence in returns. Recent earnings show strong profitability, yet market indicators suggest caution due to expected negative returns. Analyst consensus remains positive, highlighting potential for growth, supported by strategic news events.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.